EPICARDIAL ADIPOSE TISSUE THICKNESS - AN ALTERNATIVE TO WAIST CIRCUMFERENCE AS A STAND-ALONE OR SECONDARY MAIN CRITERION IN METABOLIC SYNDROME DIAGNOSTICS?

Aim. To assess the potential of echocardiographically assessed epicardial adipose tissue (EAT) thickness as a predictor of high cardiovascular risk (CVR) and subclinical target organ damage (STOD) in patients with abdominal obesity (AO). Material and methods. In 132 normotensive AO patients (mean age 45,0±5,3 years), the following parameters were assessed: lipid and carbohydrate profile, glomerular filtration rate, microalbuminuria, and CVR levels by the SCORE scale. Triplex ultrasound of brachiocephalic arteries, echocardiography, bifunctional 24-hour blood pressure monitoring and arterial stiffness assessment were also performed.

Results. Mean levels of EAT thickness were significantly different across age groups (4,2±1,0 mm in those aged 31-45 years vs. 5,1±1,1 mm in those aged 46-55 years; р<0,001). Metabolic syndrome (MS) was diagnosed in 74 (56,1%) patients, based on the presence of AO and 2 additional criteria. In this group, the prevalence of STOD was relatively low. The combination of AO and EAT thickness >75% percentile for each age group (4,8 mm for 31-45-year-olds and 5,8 mm for 46-55-year-olds) was regarded as an alternative predictor of high CVR and STOD, observed in 38 (28,8%) patients. These individuals demonstrated a significantly higher prevalence of STOD (microalbuminuria, carotid atherosclerosis, carotid wall hypertrophy, left ventricular hypertrophy, and increased arterial stiffness). The alternative prognostic model was significantly more effective than the conventional one in terms of the identification of individuals with subclinical carotid atherosclerosis. Conclusion. The alternative model for predicting high CVR and STOD in AO patients, which included the combination of such criteria of visceral obesity as AO and EAT thickness >75% percentile for each age group (4,8 mm for those aged 31-45 years and 5,8 mm for those aged 46-55 years), did not perform any worse than the conventional MS model. Of note, the alternative markers of visceral obesity were significantly more prevalent in patients who had both sets of criteria. AO patients with EAT thickness >75% percentile require further screening for carotid atherosclerosis.

1. Poirier P, Giles T, Bray G, et al. Obesity, cardiovascular disease: pathophysiology, evaluation, effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113:898-918.

2. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359:2105-20.

3. Juge-Aubry C, Henrichot E, Meier C. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005; 19 (4):547-66.

4. Han S, Quon M, Kim J, et al. Adiponectin and cardiovascular disease: response to thera¬peutic interventions. J Am Coll Cardiol 2007; 49:531-8.

5. lacobellis G, Assael F, Ribaudo M, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res, 2003, 11:304-10.

6. lacobellis G, Ribaudo M, Assael F, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003, 88 (11):5163-68.

7. Chumakova GA, Veselovskaya NG, Gritsenko OV, et al. Epicardial obesity as a possible marker of metabolic syndrome. Kardiosomatika 2012; 4:51-4. Russian (Чумакова Г. А., Веселовская Н.Г, Гриценко О.В. и др. Эпикардиальное ожирение как возможный маркер метаболического синдрома. Кардиосоматика 2012; 4:51-4).

8. Druzhilov MA, Otmakhov VV, Beteleva YuE, et al. Epicardial fat pad and rates of cardiovas¬cular remodeling in normotensive patients with abdominal obesity. Serdechnaja nedosta- tochnost' 2013; 14 (1):22-8. Russian (Дружилов М. А., Отмахов В.В., Бетелева Ю. Е. и др. Эпикардиальный жир и показатели кардиоваскулярного ремоделирования

9. у нормотензивных пациентов с абдоминальным ожирением. Сердечная недостаточность 2013; 14 (1):22-8).

10. Diagnostics and treatment of metabolic syndrome. In. National clinical guidelines 3th ed. Moscow: Silicea-Poligraf; 2010: 277-316. Russian (Диагностика и лечение метаболического синдрома. В кн: Национальные клинические рекомендации. 3-е издание. М.: Силицея-Полиграф; 2010.: 277-316).

11. Pierdomenico S, Pierdomenico A, Cuccurullo F, et al. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 2013; 111 (1):73-8.

12. European Guidelines on cardiovascular disease prevention in clinical practice (ver¬sion 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635-701.

13. Diagnostics and treatment of arterial hypertension. In. National clinical guidelines 3th ed. Moscow: Silicea-Poligraf; 2010: 464-500. Russian (Диагностика и лечение артериальной гипертензии. В кн: Национальные клинические рекомендации. 3-е издание. М.: Силицея-Полиграф; 2010: 464-500).

14. Posokhov IN. Pulse wave velocity 24-hour monitoring with one-site measurements by oscillometry. Medical Devices: Evidence and Research 2013; 6:11-5.

15. Sugawara J, Hayashi K, Tanaka H, et al. Carotid-femoral pulse wave velocity: Impact of different arterial path length measurements. Artery Research 2010; 4:27-31.

16. Flegal K, Kit B, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories. JAMA 2013; 309 (1):71-82.